RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

被引：0
|
作者：
Catherine S. Tripp
Carolyn Cuff
Andrew L. Campbell
Barbara A. Hendrickson
Jeff Voss
Terry Melim
Chengbin Wu
Andrew D. Cherniack
Kenneth Kim
机构：
[1] AbbVie,
[2] Global Pharmaceutical R&D,undefined
[3] AbbVie,undefined
[4] Global Pharmaceutical R&D,undefined
[5] WCCT Global LLC,undefined
[6] EpimAb Biotherapeutics Inc.,undefined
[7] Broad Institute of MIT and Harvard,undefined
来源：
Advances in Therapy | 2017年 / 34卷
关键词：
Asthma; IL-13; Respiratory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1364 / 1381
页数：17
相关论文
共 50 条
  • [1] RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study
    Tripp, Catherine S.
    Cuff, Carolyn
    Campbell, Andrew L.
    Hendrickson, Barbara A.
    Voss, Jeff
    Melim, Terry
    Wu, Chengbin
    Cherniack, Andrew D.
    Kim, Kenneth
    ADVANCES IN THERAPY, 2017, 34 (06) : 1364 - 1381
  • [2] THE CHARACTERIZATION OF RPC4046, A NOVEL ANTI-IL13 MONOCLONAL ANTIBODY THAT BLOCKS BINDING TO IL-13 RECEPTOR α1 AND α 2 IN DEVELOPMENT FOR EOSINOPHILIC ESOPHAGITIS: RESULTS OF A FIRST-IN-HUMAN STUDY.
    Tripp, C.
    Campbell, A.
    Hendrickson, B.
    Cuff, C.
    Miller, R.
    Wu, C.
    Kim, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A104 - A105
  • [3] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY RPC4046 IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
    Hirano, I.
    Collins, M.
    Assouline-Dayan, Y.
    Evans, L.
    Gupta, S.
    Schoepfer, A.
    Straumann, A.
    Rodriguez, C.
    Hua, S.
    Dellon, E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S15 - S15
  • [4] A Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Recombinant, Humanized, Anti-Interleukin-13 Monoclonal Antibody (RPC4046) in Patients with Active Eosinophilic Esophagitis: Results of the HEROES Study
    Dellon, Evan S.
    Collins, Margaret
    Assouline-Dayan, Yehudith
    Evans, Larry
    Gupta, Sandeep K.
    Schoepfer, Alain
    Straumann, Alex
    Grimm, Michael
    Smith, Heather
    Tompkins, Cindy-ann
    Woo, Amy
    Peach, Robert
    Frohna, Paul A.
    Gujrathi, Sheila
    Aranda, Richard
    Olson, Allan
    Penenberg, Darryl
    Hirano, Ikuo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S186 - S186
  • [5] A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
    Hodsman, Peter
    Ashman, Claire
    Cahn, Anthony
    De Boever, Erika
    Locantore, Nicholas
    Serone, Adrian
    Pouliquen, Isabelle
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 118 - 128
  • [6] Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers
    Cevikbas, Ferda
    Ward, Alison
    Firth, Carl
    Veverka, Karen
    CLINICAL IMMUNOLOGY, 2023, 253
  • [7] A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
    Lee, Jieon
    Kim, Bo-Hyung
    Yu, Kyung-Sang
    Kim, Hee Sun
    Kim, Ji Duck
    Cho, Joo-Youn
    Lee, SeungHwan
    Gu, Namyi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1301 - 1313
  • [8] First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
    Blank, Antje
    Hohmann, Nicolas
    Dettmer, Marlen
    Manka-Stuhlik, Anette
    Mikus, Gerd
    Stoll, Felicitas
    Stuetzle-Schnetz, Marlies
    Thomas, Daniel
    Exner, Evelyn
    Schmitt-Bormann, Beate
    Schaller, Torsten
    Laage, Rico
    Schoenborn-Kellenberger, Oliver
    Arndt, Michaela
    Haefeli, Walter E.
    Krauss, Juergen
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (10): : 2366 - 2377
  • [9] Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
    Busse, William W.
    Holgate, Stephen
    Kerwin, Edward
    Chon, Yun
    Feng, JingYuan
    Lin, Joseph
    Lin, Shao-Lee
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (11) : 1294 - 1302
  • [10] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
    Choy, EHS
    Isenberg, DA
    Garrood, T
    Farrow, S
    Ioannou, Y
    Bird, H
    Cheung, N
    Williams, B
    Hazleman, B
    Price, R
    Yoshizaki, K
    Nishimoto, N
    Kishimoto, T
    Panayi, GS
    ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3143 - 3150
12345